比较性尿道代谢学揭示了COVID-19和肝脏疾病的独特和共享的途径
Garima Juyal1, Fariya Khan2,3, Sidra Siddiqui2
1Department of Biotechnology, SEAS, Bennett University, 201310, Greater Noida, Uttar Pradesh, India. garima.juyal@bennett.edu.in.
Metabolomics : Official journal of the Metabolomic Society
|February 27, 2026
概括
COVID-19和肝脏疾病导致代谢变化. 这项研究为每个疾病确定了独特的尿路代谢特征,提供了潜在的诊断生物标志物和治疗点.
科学领域:
- 代谢学 代谢学 代谢学
- 系统生物学 系统生物学
- 发现疾病生物标志物的发现.
背景情况:
- COVID-19和肝脏疾病诱导显著的代谢障碍.
- 这些代谢变化背后的精确机制尚未完全理解.
研究的目的:
- 为了比较COVID-19患者,肝病患者和健康对照者的尿道代谢概况.
- 为了确定共同和独特的代谢特征区分这些条件.
主要方法:
- 使用液态染色体质谱法 (LC-MS) 进行非向的尿道代谢分析.
- 分析包括差异化代谢物丰度,途径丰富,网络拓和机器学习 (随机森林).
- 分析了来自COVID-19患者 (n=102),肝病患者 (n=100) 和健康对照组 (n=101) 的样本.
主要成果:
- 无论是COVID-19还是肝病,都显示出大量的代谢重编程.
- COVID-19的特点是抑制了维生素B6和纯素代谢;肝脏疾病显示胆酸和泛氨酸代谢减少.
- 机器学习模型准确地区分疾病状态,识别独特的生物标志物,如N-Acetylvaline (COVID-19) 和胆酸衍生物 (肝病).
结论:
- 研究结果阐明了COVID-19和肝脏疾病中的疾病特异性代谢重塑.
- 鉴定到的独特代谢物可以作为诊断和治疗策略的潜在生物标志物.
更多相关视频
相关概念视频
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
250
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
Urine Studies I: Urinalysis
1.8K
Urinalysis is a widely used diagnostic test that analyzes urine's physical, chemical, and microscopic characteristics. Healthcare providers use it to detect and monitor various health conditions, including renal disease, urinary tract infections (UTIs), diabetes, and metabolic or systemic disorders.Components of UrinalysisUrinalysis consists of three primary components: physical, chemical, and microscopic examination. Each provides unique insights into the urine sample and, by extension, the...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
267
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
267


